Cargando…
Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients
BACKGROUND: Mastocytosis is a rare disease characterised by the accumulation and/or proliferation of abnormal mast cells (MCs) in one or several organs. It may present with a number of different symptoms that involve various organ systems. The current study aims to assess the prevalence of MC mediat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934538/ https://www.ncbi.nlm.nih.gov/pubmed/33673856 http://dx.doi.org/10.1186/s13023-021-01747-y |
_version_ | 1783660835010248704 |
---|---|
author | Jendoubi, Fatma Severino-Freire, Maella Negretto, Mathilde Arbus, Christophe Paul, Carle Bulai Livideanu, Cristina |
author_facet | Jendoubi, Fatma Severino-Freire, Maella Negretto, Mathilde Arbus, Christophe Paul, Carle Bulai Livideanu, Cristina |
author_sort | Jendoubi, Fatma |
collection | PubMed |
description | BACKGROUND: Mastocytosis is a rare disease characterised by the accumulation and/or proliferation of abnormal mast cells (MCs) in one or several organs. It may present with a number of different symptoms that involve various organ systems. The current study aims to assess the prevalence of MC mediator-related symptoms in a cohort of mastocytosis patients with a specific focus on neurological, psychiatric, cognitive and sexual symptoms. We also assessed the impact of the disease on patients’ professional lives. Patients were administered a validated multidimensional questionnaire to collect information on patients’ perception of the severity of their symptoms. From the questionnaires we extracted the neurological, cognitive, psychiatric and sexual symptoms and the impact of the disease on patients’ professional lives as well as their grading. The affective status was assessed using the 17-item version of the Hamilton Depression Rating Scale. RESULTS: We included 139 patients. Mastocytosis was classified as systemic in 113 patients and cutaneous in 26 patients. The prevalence of MC mediator-related systemic symptoms was as follows: cutaneous (71%), gastro-intestinal (48%), cardio-vascular (36%), musculoskeletal (26.6%), fatigue (24%), urinary (14.4%) and respiratory (10%). Headaches and vertigo were noted in respectively 55% and 32% of patients. Irritability, episodes of memory loss and difficulty concentrating were reported in 54%, 52% and 40% of cases, respectively. Sexual impairment was noted in 24% of patients. No associations were found between neuropsychiatric/cognitive impairment and age, gender, diagnostic delay, disease form, the presence of cutaneous lesions, the level of serum and bone marrow tryptase and the presence of KIT mutation in bone marrow and/or skin. Depression was noted in 49% of patients. One in four patients reported a negative impact of the disease on their professional lives. CONCLUSION: This current study provides some insights regarding symptoms related to mastocytosis and their impact on patients’ professional lives. |
format | Online Article Text |
id | pubmed-7934538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79345382021-03-08 Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients Jendoubi, Fatma Severino-Freire, Maella Negretto, Mathilde Arbus, Christophe Paul, Carle Bulai Livideanu, Cristina Orphanet J Rare Dis Research BACKGROUND: Mastocytosis is a rare disease characterised by the accumulation and/or proliferation of abnormal mast cells (MCs) in one or several organs. It may present with a number of different symptoms that involve various organ systems. The current study aims to assess the prevalence of MC mediator-related symptoms in a cohort of mastocytosis patients with a specific focus on neurological, psychiatric, cognitive and sexual symptoms. We also assessed the impact of the disease on patients’ professional lives. Patients were administered a validated multidimensional questionnaire to collect information on patients’ perception of the severity of their symptoms. From the questionnaires we extracted the neurological, cognitive, psychiatric and sexual symptoms and the impact of the disease on patients’ professional lives as well as their grading. The affective status was assessed using the 17-item version of the Hamilton Depression Rating Scale. RESULTS: We included 139 patients. Mastocytosis was classified as systemic in 113 patients and cutaneous in 26 patients. The prevalence of MC mediator-related systemic symptoms was as follows: cutaneous (71%), gastro-intestinal (48%), cardio-vascular (36%), musculoskeletal (26.6%), fatigue (24%), urinary (14.4%) and respiratory (10%). Headaches and vertigo were noted in respectively 55% and 32% of patients. Irritability, episodes of memory loss and difficulty concentrating were reported in 54%, 52% and 40% of cases, respectively. Sexual impairment was noted in 24% of patients. No associations were found between neuropsychiatric/cognitive impairment and age, gender, diagnostic delay, disease form, the presence of cutaneous lesions, the level of serum and bone marrow tryptase and the presence of KIT mutation in bone marrow and/or skin. Depression was noted in 49% of patients. One in four patients reported a negative impact of the disease on their professional lives. CONCLUSION: This current study provides some insights regarding symptoms related to mastocytosis and their impact on patients’ professional lives. BioMed Central 2021-03-05 /pmc/articles/PMC7934538/ /pubmed/33673856 http://dx.doi.org/10.1186/s13023-021-01747-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Jendoubi, Fatma Severino-Freire, Maella Negretto, Mathilde Arbus, Christophe Paul, Carle Bulai Livideanu, Cristina Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients |
title | Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients |
title_full | Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients |
title_fullStr | Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients |
title_full_unstemmed | Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients |
title_short | Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients |
title_sort | neuropsychiatric, cognitive and sexual impairment in mastocytosis patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934538/ https://www.ncbi.nlm.nih.gov/pubmed/33673856 http://dx.doi.org/10.1186/s13023-021-01747-y |
work_keys_str_mv | AT jendoubifatma neuropsychiatriccognitiveandsexualimpairmentinmastocytosispatients AT severinofreiremaella neuropsychiatriccognitiveandsexualimpairmentinmastocytosispatients AT negrettomathilde neuropsychiatriccognitiveandsexualimpairmentinmastocytosispatients AT arbuschristophe neuropsychiatriccognitiveandsexualimpairmentinmastocytosispatients AT paulcarle neuropsychiatriccognitiveandsexualimpairmentinmastocytosispatients AT bulailivideanucristina neuropsychiatriccognitiveandsexualimpairmentinmastocytosispatients |